These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32366210)

  • 1. PD-L1 expression level in different thymoma stages and thymic carcinoma: a meta-analysis.
    Chen HF; Wu LX; Li XF; Zhu YC; Pan WW; Wang WX; Xu CW; Huang JH; Wu MH; Du KQ
    Tumori; 2020 Aug; 106(4):306-311. PubMed ID: 32366210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
    Marchevsky AM; Walts AE
    Hum Pathol; 2017 Feb; 60():16-23. PubMed ID: 27746267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach.
    Berardi R; Goteri G; Brunelli A; Pagliaretta S; Paolucci V; Caramanti M; Rinaldi S; Refai M; Pompili C; Morgese F; Torniai M; Marcantognini G; Ricci G; Mazzanti P; Onofri A; Bianchi F; Sabbatini A; Cascinu S
    Expert Opin Ther Targets; 2020 Sep; 24(9):937-943. PubMed ID: 32662701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.
    Owen D; Chu B; Lehman AM; Annamalai L; Yearley JH; Shilo K; Otterson GA
    J Thorac Oncol; 2018 Aug; 13(8):1204-1212. PubMed ID: 29702286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic Features of Thymoma With the Expression of Programmed Death Ligand 1.
    Hakiri S; Fukui T; Mori S; Kawaguchi K; Nakamura S; Ozeki N; Kato T; Goto M; Yatabe Y; Yokoi K
    Ann Thorac Surg; 2019 Feb; 107(2):418-424. PubMed ID: 30312607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms.
    Weissferdt A; Fujimoto J; Kalhor N; Rodriguez J; Bassett R; Wistuba II; Moran CA
    Mod Pathol; 2017 Jun; 30(6):826-833. PubMed ID: 28281549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.
    Katsuya Y; Fujita Y; Horinouchi H; Ohe Y; Watanabe S; Tsuta K
    Lung Cancer; 2015 May; 88(2):154-9. PubMed ID: 25799277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature.
    Guleria P; Husain N; Shukla S; Kumar S; Parshad R; Jain D
    Ann Diagn Pathol; 2018 Jun; 34():135-141. PubMed ID: 29661720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
    Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
    Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
    Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
    PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death-ligand 1 expression profiling in thymic epithelial cell tumors: Clinicopathological features and quantitative digital image analyses.
    Ishihara S; Okada S; Ogi H; Kodama Y; Shimomura M; Tsunezuka H; Itoh K; Marx A; Inoue M
    Lung Cancer; 2020 Jul; 145():40-47. PubMed ID: 32402921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.
    Rajan A; Heery CR; Thomas A; Mammen AL; Perry S; O'Sullivan Coyne G; Guha U; Berman A; Szabo E; Madan RA; Ballester LY; Pittaluga S; Donahue RN; Tsai YT; Lepone LM; Chin K; Ginty F; Sood A; Hewitt SM; Schlom J; Hassan R; Gulley JL
    J Immunother Cancer; 2019 Oct; 7(1):269. PubMed ID: 31639039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic impact of programmed cell death 1 and its ligand and the correlation with epithelial-mesenchymal transition in thymic carcinoma.
    Funaki S; Shintani Y; Fukui E; Yamamoto Y; Kanzaki R; Ose N; Kanou T; Minami M; Mori E; Okumura M
    Cancer Med; 2019 Jan; 8(1):216-226. PubMed ID: 30600651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma.
    Wei YF; Chu CY; Chang CC; Lin SH; Su WC; Tseng YL; Lin CC; Yen YT
    Lung Cancer; 2018 Nov; 125():35-42. PubMed ID: 30429036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors.
    Chen Y; Zhang Y; Chai X; Gao J; Chen G; Zhang W; Zhang Y
    Biomed Res Int; 2018; 2018():5830547. PubMed ID: 29850538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor immunity is related to
    Imai H; Kaira K; Hashimoto K; Nitanda H; Taguchi R; Yanagihara A; Umesaki T; Yamaguchi O; Mouri A; Kawasaki T; Yasuda M; Kobayashi K; Sakaguchi H; Kuji I; Kagamu H
    Cancer Med; 2021 Sep; 10(18):6317-6326. PubMed ID: 34363337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy.
    Katsuya Y; Horinouchi H; Asao T; Kitahara S; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Watanabe S; Tsuta K; Ohe Y
    Lung Cancer; 2016 Sep; 99():4-10. PubMed ID: 27565906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation of amplification of chromosome 1 with histologic typing of thymic epithelial tumors].
    Ma YQ; Zhang C; Cui WL; Gulinaer A; Zhang W; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):820-4. PubMed ID: 22336207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
    Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
    Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets.
    Enkner F; Pichlhöfer B; Zaharie AT; Krunic M; Holper TM; Janik S; Moser B; Schlangen K; Neudert B; Walter K; Migschitz B; Müllauer L
    Pathol Oncol Res; 2017 Jul; 23(3):551-564. PubMed ID: 27844328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.